In this issue:
Oral semaglutide formulation for type 2 diabetes
Population type 2 diabetes screening and CV/mortality risk
Effect of type 2 diabetes screening on CV/mortality risk
Maternal BMI predicts large-forgestational- age
Lower-limb amputations in EMPA-REG
Novel dual GIT/GLP-1 agonist in type 2 diabetes
Intensified intervention and CV/mortality outcomes in type 2 diabetes
Correlations in adults with HNF1B molecular defects
Sulfonylurea pharmacology and CV/hypoglycaemic event risk
Please login below to download this issue (PDF)